What is certain is that as we delve deeper into the molecular landscape of AML, the significance of TP53 mutations becomes increasingly apparent, thus requiring a paradigm shift in our clinical strategies, with hopes of fostering a brighter future for patients with TP53mut AML. The gene discussed is TP53; the disease is acute myeloid leukemia.